Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences

Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hanne Haahr, Tim Heise
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	faster aspart pharmacokinetic pharmacodynamic clamp Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/8f6ea16d2b274e568069cac42f9f1865
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f6ea16d2b274e568069cac42f9f1865
record_format	dspace
spelling	oai:doaj.org-article:8f6ea16d2b274e568069cac42f9f18652021-11-14T09:00:23ZFast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences2072-03512072-037810.14341/DM12357https://doaj.org/article/8f6ea16d2b274e568069cac42f9f18652020-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12357https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.Hanne HaahrTim HeiseEndocrinology Research Centrearticlefaster aspartpharmacokineticpharmacodynamicclampNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 2, Pp 140-160 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	faster aspart pharmacokinetic pharmacodynamic clamp Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	faster aspart pharmacokinetic pharmacodynamic clamp Nutritional diseases. Deficiency diseases RC620-627 Hanne Haahr Tim Heise Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
description	Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.
format	article
author	Hanne Haahr Tim Heise
author_facet	Hanne Haahr Tim Heise
author_sort	Hanne Haahr
title	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
title_short	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
title_full	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
title_fullStr	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
title_full_unstemmed	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
title_sort	fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/8f6ea16d2b274e568069cac42f9f1865
work_keys_str_mv	AT hannehaahr fastactinginsulinaspartareviewofitspharmacokineticandpharmacodynamicpropertiesandtheclinicalconsequences AT timheise fastactinginsulinaspartareviewofitspharmacokineticandpharmacodynamicpropertiesandtheclinicalconsequences
_version_	1718429475457204224

Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences

Ejemplares similares